Abstracts tagged "Disease Activity"

Abstract Number: 2828 • 2014 ACR/ARHP Annual Meeting
A Physically Demanding Job May Amplify the Effect of Disease Activity on the Development of Syndesmophytes in Patients with Ankylosing Spondylitis
Sofia Ramiro^1,2, A.M. van Tubergen³, Robert Landewé^4,5, Annelies Boonen⁶, Carmen Stolwijk⁷, Maxime Dougados⁸, Filip van Den Bosch⁹ and Desiree van der Heijde¹⁰, ¹Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center/University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ³Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Atrium Medical Center, Heerlen, Netherlands, ⁶Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁷Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁸Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁹Ghent University Hospital, Ghent, Belgium, ¹⁰Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: We have recently shown that disease activity is longitudinally associated with radiographic progression in AS. In animal models, it has recently been shown that…
Abstract Number: 2456 • 2014 ACR/ARHP Annual Meeting
Associations of Toll-like Receptor (TLR)-4 Single Nucleotide Polymorphisms and Rheumatoid Arthritis Disease Progression
Marshall Davis¹, Tricia LeVan², Fang Yu³, Harlan Sayles⁴, Jeremy Sokolove⁵, William H. Robinson⁶, Kaleb Michaud⁷, Geoffrey M Thiele⁸ and Ted R. Mikuls⁴, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Univ of Nebraska Med Ctr, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁶VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷National Data Bank for Rheumatic Diseases, Wichita, KS, ⁸Omaha VA and the University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Toll-like receptor (TLR)-4 signaling pathways have been implicated in both the innate and adaptive immune responses that characterize rheumatoid arthritis (RA). In this study,…
Abstract Number: 1921 • 2014 ACR/ARHP Annual Meeting
The Deposition of Complement C4d Split Product on Platelets and Erythrocytes Correlate with Disease Activity and Improvement in Systemic Lupus Erythematosus
Joan T. Merrill¹, Aikaterini Thanou², Stan Kamp¹, John Conklin³, Derren Barken⁴ and Thierry Dervieux⁵, ¹Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ⁴Exagen Diagnostics, Inc., Vista, CA, ⁵rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: We sought to evaluate the usefulness of cell bound complement activation products (C4d deposition on erythrocytes [EC4d] and platelets [PC4d]) in the monitoring of…
Abstract Number: 1452 • 2014 ACR/ARHP Annual Meeting
Timing of Decisions to Adjust Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting
Yomei Shaw¹, Chung-Chou H. Chang², Marc C. Levesque³, Julie M. Donohue⁴, Kaleb Michaud^5,6 and Mark S. Roberts¹, ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ⁴Health Policy & Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁵National Data Bank for Rheumatic Diseases, Wichita, KS, ⁶Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Current guidelines recommend that rheumatoid arthritis (RA) patients with poor response to their current regimen of disease modifying anti-rheumatic drugs (DMARDs) have therapy adjusted…
Abstract Number: 1053 • 2014 ACR/ARHP Annual Meeting
Co-Morbidity Is Associated with Disease Severity in Early Rheumatoid Arthritis
Christopher Sparks¹, Aleena Abdullah², Steven Zhao³, Cristina Estrach³ and Nicola Goodson¹, ¹Musculoskeletal Biology1, University of Liverpool, Liverpool, United Kingdom, ²Musculoskeletal biology1, University of Liverpool, Liverpool, United Kingdom, ³Rheumatology, University Hospital Aintree, Liverpool, United Kingdom
Background/Purpose Co-morbidity has been shown to increase length of hospital stay and mortality in hospitalised patients. However, in early rheumatoid arthritis (eRA) co-morbidity may confound…
Abstract Number: 709 • 2014 ACR/ARHP Annual Meeting
Impact of Sleep Disorders in Quality of Life, Pain and Disease Activity Using Actigraphy and Pittsburgh Sleep Quality Index (PSQI)in Female with Systemic Lupus Ertyhematosus (SLE).
Lilian Reis¹, Marco Tulio de Mello² and Virginia M. Trevisani³, ¹Internal medicine and therapy, Federal University of Sao Paulo - UNIFESP, SAO PAULO, Brazil, ²Department of Psychobiology, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ³Federal University of São Paulo, São Paulo Brazil, Brazil
Background/Purpose Despite the fact that sleep disorders are poorly studied, they´re a frequent complain by patients with SLE (62 to 80% related) and others found…
Abstract Number: 383 • 2014 ACR/ARHP Annual Meeting
How Low Is Low Disease Activity? an Analysis from a Prospective, Observational Registry
Edward C. Keystone¹, Boulos Haraoui², John Kelsall³, Carter Thorne⁴, Philip Baer⁵, William Bensen⁶, Denis Choquette⁷, Regan Arendse⁸, Dalton Sholter⁹, Niall Jones¹⁰, Algis Jovaisas¹¹, Emmanouil Rampakakis¹², John S. Sampalis¹², Francois Nantel¹³, May Shawi¹³, Allen J Lehman¹⁴ and Susan Otawa¹⁴, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²University of Montreal Hospital Centre, Montreal, QC, Canada, ³The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁴Southlake Regional Health Centre, Newmarket, ON, Canada, ⁵Private Practice, Scarborough, ON, Canada, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁸University of Saskatchewan, Saskatoon, SK, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Dept of Rheumatology, University of Alberta, Edmonton, AB, Canada, ¹¹194 Main Street, University of Ottawa, Ottawa, ON, Canada, ¹²JSS Medical Research, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Composite measures of disease activity can facilitate clinical decision-making to achieve treatment goals, and treating-to-target has been shown to improve outcomes. Both CRA and…
Abstract Number: 136 • 2014 ACR/ARHP Annual Meeting
Serum Calprotectin (S100A8/9) Is an Independent Predictor of Ultrasound Synovitis in Patients with Rheumatoid Arthritis
Jana Hurnakova¹, Jakub Zavada¹, Petra Hanova², Hana Hulejova¹, Martin Klein¹, Herman F. Mann¹, Olga Sleglova¹, Martina Olejarova¹, Sarka Forejtova³, Olga Ruzickova¹, Martin Komarc⁴, Karel Pavelka¹ and Ladislav Senolt³, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ²Institute of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁴Institute of biophysics and informatics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose Serological biomarkers specifically reflecting pathological processes may have added value in assessing joint inflammation in rheumatoid arthritis (RA). Calprotectin (S100A8/9 protein) has been demonstrated…
Abstract Number: 2813 • 2014 ACR/ARHP Annual Meeting
Correlation of Morning Stiffness with Measures of Higher Disease Activity in a Large US Registry Population of Rheumatoid Arthritis Patients
Vibeke Strand¹, Robert J. Holt², Katherine C. Saunders³, Jeffery D. Kent⁴, Ping Xu⁵, Amy Y. Grahn⁴, Marc Mason³ and Carol J. Etzel^6,7, ¹Stanford University, Palo Alto, CA, ²University of Illinois - Chicago, Chicago, IL, ³Corrona, LLC., Southborough, MA, ⁴Horizon Pharma, Inc., Deerfield, IL, ⁵Axio Research LLC, Seattle, WA, ⁶PO Box 786, Corrona, LLC., Southborough, MA, ⁷Department of Epidemiology, UT MD Anderson, Houston, TX
Background/Purpose : Morning stiffness may not be specifically queried by rheumatologists in the course of their regular interactions with rheumatoid arthritis (RA) patients. This analysis…
Abstract Number: 2451 • 2014 ACR/ARHP Annual Meeting
Mir-155 Expression Correlates with Clinical Disease Activity and Has Effector Function in Rheumatoid Arthritis
Aziza Elmesmari¹, Derek G. Gilchrist², Mariola Kurowska-Stolarska³ and Iain B. McInnes⁴, ¹Immunology, Institute of Infection,Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: MicroRNAs are fine tuners of biological pathways that function via post-transcriptional regulation of target mRNA life span. MicroRNA 155 (miR155) is particularly implicated in…
Abstract Number: 1920 • 2014 ACR/ARHP Annual Meeting
Predicting SLE Disease Activity in the Next Year Based on Measures of Four Gene Transcripts and Two Proteins
Laurence S Magder¹, Eric Zollars², Jadwiga Bienkowska³, Chris Stebbins⁴, Carrie Wager⁵, Linda Burkly⁶, Nicolas Wisniacki⁷, Ann Ranger⁸ and Michelle Petri⁹, ¹Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Translational Medicine, Biogen Idec, Cambridge, MA, ⁵Biostatistics, Biogen Idec, Cambridge, MA, ⁶Biogen Idec, Cambridge, MA, ⁷Formerly with Biogen Idec, Cambridge, MA, ⁸14 Cambridge Center, Biogen Idec, Cambridge, MA, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose Multiple gene transcripts and proteins in blood or urine have been observed to correlate with disease activity in SLE. However some observed associations might…
Abstract Number: 1426 • 2014 ACR/ARHP Annual Meeting
Periodontal disease and Clinical Activity of Rheumatoid Arthritis Patients
Daniel Xibille-Friedmann¹, Jose Ivan Martinez Rivera², Jaqueline Rodriguez Amado³, Carolina Bustos Rivera Bahena⁴, Marisol Sandoval Rios⁵ and Jose Luis Montiel Hernandez⁶, ¹Rheumatology, Hospital General de Cuernavaca, Cuernavaca, Mexico, ²Instituto Nacional de Salud Publica, Cuernavaca, Mexico, ³Universidad Autónoma de Nuevo Leon, Centro de Investigación y Desarrollo en Ciencias de la Salud, Monterrey, Mexico, ⁴Universidad Autonoma del Estado de Morelos, Science Faculty, Cuernavaca, Mexico, ⁵Universidad Autonoma del Estado de Morelos, Faculty of Pharmacy, Cuernavaca, Mexico, ⁶Cytokines and Autoimmunity Laboratory, Faculty of Pharmacy, Universidad Autónoma del Estado de Morelos, Cuernavaca, México, Cuernavaca, Mexico
Background/Purpose: Although several studies have suggested the association between periodontitis, infection by Porphyromona gingivalisand Rheumatoid Arthritis disease activity, its relationship with periodontal disease, oral and…
Abstract Number: 1051 • 2014 ACR/ARHP Annual Meeting
Rates of Renal Remission with Immunosuppressives in Lupus Nephritis: A Systematic Review and Network Meta-Analysis
Jasvinder A. Singh¹, Ahmed Kotb², Alomgir Hossain², Amy Mudano³ and George Wells⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Ottawa, Ottawa, ON, Canada, ³Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁴Cardiovascular Resarch Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose To compare renal remission rates with immunosuppressives by performing a systematic review and network meta-analyses (NMA) of RCTs of lupus nephritis. Methods We performed…
Abstract Number: 687 • 2014 ACR/ARHP Annual Meeting
Effect of Corticosteroid Use By Dose on the Risk of Developing Organ Damage over Time in Systemic Lupus Erythematosus—the Hopkins Lupus Cohort
Sarah Al Sawah¹, Xiang Zhang¹, Baojin Zhu¹, Laurence S. Magder², Shonda A Foster¹, Noriko Iikuni¹ and Michelle Petri³, ¹Eli Lilly and Company, Indianapolis, IN, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Reduction of corticosteroid dose remains an important goal in the management of systemic lupus erythematosus (SLE). Current standard of care in SLE relies heavily…
Abstract Number: 384 • 2014 ACR/ARHP Annual Meeting
Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient Activity Score (PAS) and Routine Assessment of Patient Index Data (RAPID)
Erin Carruthers¹, Noura AL Osaimi², Charles H Goldsmith³, Paul Adam⁴ and Diane Lacaille⁵, ¹Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁵Arthritis Research Centre of Canada, Vancouver, BC, Canada
Background/PurposeIn RA the target for treatment is clinical remission or minimal disease activity. Patient involvement in monitoring their disease activity could enhance treatment by providing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.